In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

The following rewritten from UVM tests/05components/50in_order/20int gives a false Verilation error: %Error: t/t_0.v:16:43: Reference to 'T' type would form a ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

Consistently ranked among the top by U.S. News & World Report, the online Master of Science in Electrical & Computer Engineering offers engineering professionals flexibility without sacrificing ...

As companies like Amazon and Microsoft lay off workers and embrace A.I. coding tools, computer science graduates say they’re struggling to land tech jobs. Manasi Mishra recently graduated from Purdue ...

Mikeie Reiland is a staff writer for Education at Forbes Advisor. Before coming to Forbes Advisor, he wrote magazine journalism for publications like the Oxford American, Bitter Southerner, and Gravy.

Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of the AI biotech’s pipeline. Shrinking the Salt Lake City-based company’s ...

Shares of Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) are trading higher after the company, in collaboration with MIT, announced the release of Boltz-2, a new open-source AI model designed to predict ...

The results of a recent survey released Tuesday showed President Trump's actions are likely to make it harder for biotech companies like Recursion to raise capital. The company reported ...

Abstract: We observe that the computational inefficiency of branched recursive functions was not appropriately covered in almost all textbooks for computer science courses in the first three years of ...

The business of using artificial intelligence to find new drugs is starting to consolidate. The AI-powered drug discovery firm Recursion Pharmaceuticals will buy rival Exscientia in an all-stock deal ...